/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Dermata Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.3 0.0067(0.67%) DRMA at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 2.91
Highest Today 3.016
Today’s Open 2.9185
Prev. Close 2.99
52 Week High 16.50
52 Week Low 2.36
Day’s Range: Low 2.91 High 3.016
52-Week Range: Low 2.36 High 16.50
1 day return -
1 Week return -0.33
1 month return -2.9
3 month return -44.46
6 month return +353.99
1 year return +140.8
3 year return -95.13
5 year return -
10 year return -

Institutional Holdings

UBS Group AG 1.33

Geode Capital Management, LLC 0.40

Fidelity Extended Market Index 0.24

JONES FINANCIAL COMPANIES LLLP 0.18

Fidelity Series Total Market Index 0.16

Tower Research Capital LLC 0.08

SBI Securities Co Ltd 0.01

Bank of America Corp 0.00

Armistice Capital, LLC 0.00

SSgA U.S. Total Market Index Strategy 0.00

Wells Fargo & Co 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.07 M

PB Ratio 0.8139

PE Ratio 0.1943

Enterprise Value -1.44 M

Total Assets 3.53 M

Volume 70311

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-7330319 -7.3M, FY22:-9610913 -9.6M, FY21:-7948090 -7.9M, FY20:-3433799 -3.4M, FY19:-4972104 -5.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-1691989 -1.7M, Q2/2025:-1701093 -1.7M, Q1/2025:-2303587 -2.3M, Q3/2024:-3173156 -3.2M, Q2/2024:-2829106 -2.8M

Fund house & investment objective

Company Information Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Mr. Gerald T. Proehl

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow